Table 1 The relationship between ERβ/IL6 expression levels and clinical characteristics of NSCLC patients
No. of patients(%) | ERβ Expression | χ2 | p value | IL6 Expression | χ2 | p value | |||
|---|---|---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | ||||||
All | 289 | 258 | 31 | 270 | 19 | ||||
Gender | |||||||||
Female | 102(35.29) | 95 | 7 | 2.458 | 0.117 | 99 | 3 | 3.388 | 0.066 |
Male | 187(64.71) | 163 | 24 | 171 | 16 | ||||
Age | |||||||||
< 60 | 170(58.82) | 150 | 20 | 0.465 | 0.495 | 158 | 12 | 0.158 | 0.691 |
≥ 60 | 119(41.18) | 108 | 11 | 112 | 7 | ||||
Smoking | |||||||||
Ex | 178(61.59) | 162 | 16 | 1.462 | 0.227 | 171 | 7 | 5.266 | 0.022 |
Never | 111(38.41) | 96 | 15 | 99 | 12 | ||||
T stage | |||||||||
1a-2b | 220 (76.12) | 194 | 26 | 1.146 | 0.284 | 205 | 15 | 0.089 | 0.765 |
3–4 | 69 (23.88) | 64 | 5 | 65 | 4 | ||||
Lymph node metastasis | |||||||||
YES | 187(64.71) | 167 | 20 | 0.001 | 0.974 | 178 | 9 | 2.677 | 0.102 |
NO | 102(35.29) | 91 | 11 | 92 | 10 | ||||
Metastasis | |||||||||
YES | 24(08.30) | 18 | 6 | 5.568 | 0.018 | 20 | 4 | 4.34 | 0.037 |
NO | 265(91.70) | 240 | 25 | 250 | 15 | ||||
TNM stage | |||||||||
I-II | 175 (60.55) | 154 | 21 | 0.751 | 0.386 | 162 | 13 | 0.527 | 0.468 |
III-IV | 114(39.45) | 104 | 10 | 108 | 6 | ||||
Tumor Histology | |||||||||
SQC | 134(46.37) | 115 | 19 | 3.11 | 0.078 | 125 | 9 | 0.008 | 0.92873 |
ADC | 155(53.63) | 143 | 12 | 145 | 10 | ||||
Tumor Differentation | |||||||||
Well/Moderate | 156(53.98) | 134 | 22 | 4.034 | 0.045 | 141 | 15 | 5.104 | 0.024 |
Poor | 133(46.02) | 124 | 9 | 129 | 4 | ||||